{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:47:30Z","timestamp":1793760450457,"version":"4.6.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T00:00:00Z","timestamp":1593734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T00:00:00Z","timestamp":1593734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["5K08NS102398-02"],"award-info":[{"award-number":["5K08NS102398-02"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Gaucher disease is a lysosomal storage disorder caused by insufficient glucocerebrosidase activity. Its hallmark manifestations are attributed to infiltration and inflammation by macrophages. Current therapies for Gaucher disease include life\u2212long intravenous administration of recombinant glucocerebrosidase and orally-available glucosylceramide synthase inhibitors. An alternative approach is to engineer the patient\u2019s own hematopoietic system to restore glucocerebrosidase expression, thereby replacing the affected cells, and constituting a potential one-time therapy for this disease. Here, we report an efficient CRISPR\/Cas9-based approach that targets glucocerebrosidase expression cassettes with a monocyte\/macrophage-specific element to the CCR5 safe-harbor locus in human hematopoietic stem and progenitor cells. The targeted cells generate glucocerebrosidase-expressing macrophages and maintain long-term repopulation and multi-lineage differentiation potential with serial transplantation. The combination of a safe-harbor and a lineage-specific promoter establishes a universal correction strategy and circumvents potential toxicity of ectopic glucocerebrosidase in the stem cells. Furthermore, it constitutes an adaptable platform for other lysosomal enzyme deficiencies.<\/jats:p>","DOI":"10.1038\/s41467-020-17148-x","type":"journal-article","created":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T06:02:47Z","timestamp":1593756167000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Engineering monocyte\/macrophage\u2212specific glucocerebrosidase expression in human hematopoietic stem cells using genome editing"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3730-1662","authenticated-orcid":false,"given":"Samantha G.","family":"Scharenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0554-0295","authenticated-orcid":false,"given":"Edina","family":"Poletto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5481-6206","authenticated-orcid":false,"given":"Katherine L.","family":"Lucot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4268-2391","authenticated-orcid":false,"given":"Pasqualina","family":"Colella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Sheikali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Montine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3850-4648","authenticated-orcid":false,"given":"Matthew H.","family":"Porteus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6740-1154","authenticated-orcid":false,"given":"Natalia","family":"Gomez-Ospina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,3]]},"reference":[{"key":"17148_CR1","doi-asserted-by":"crossref","unstructured":"Stirnemann, J. et al. A review of gaucher disease pathophysiology, clinical presentation and treatments. Int. J. Mol. Sci. 18, 441 (2017).","DOI":"10.3390\/ijms18020441"},{"key":"17148_CR2","unstructured":"Pastores, G. M. & Hughes, D. A. in GeneReviews((R)). (eds Adam, M. P. et al.) (University of Washington, Seattle University of Washington, Seattle, 1993). GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved., Seattle (WA))."},{"key":"17148_CR3","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1001\/archinte.160.18.2835","volume":"160","author":"J Charrow","year":"2000","unstructured":"Charrow, J. et al. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch. Intern. Med. 160, 2835\u20132843 (2000).","journal-title":"Arch. Intern. Med."},{"key":"17148_CR4","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","volume":"361","author":"E Sidransky","year":"2009","unstructured":"Sidransky, E. et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease. N. Engl. J. Med. 361, 1651\u20131661 (2009).","journal-title":"N. Engl. J. Med."},{"key":"17148_CR5","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.bbalip.2013.11.004","volume":"1841","author":"MJ Ferraz","year":"2014","unstructured":"Ferraz, M. J. et al. Gaucher disease and Fabry disease: new markers and insights in pathophysiology for two distinct glycosphingolipidoses. Biochim. Biophys. Acta 1841, 811\u2013825 (2014).","journal-title":"Biochim. Biophys. Acta"},{"key":"17148_CR6","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature21368","volume":"543","author":"MK Pandey","year":"2017","unstructured":"Pandey, M. K. et al. Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease. Nature 543, 108\u2013112 (2017).","journal-title":"Nature"},{"key":"17148_CR7","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ymgme.2013.09.002","volume":"111","author":"MK Pandey","year":"2014","unstructured":"Pandey, M. K. et al. Gaucher disease: chemotactic factors and immunological cell invasion in a mouse model. Mol. Genet. Metab. 111, 163\u2013171 (2014).","journal-title":"Mol. Genet. Metab."},{"key":"17148_CR8","first-page":"81","volume":"6","author":"PB Deegan","year":"2012","unstructured":"Deegan, P. B. & Cox, T. M. Imiglucerase in the treatment of Gaucher disease: a history and perspective. Drug Des. Devel. Ther. 6, 81\u2013106 (2012).","journal-title":"Drug Des. Devel. Ther."},{"key":"17148_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3109\/08880018.2012.762076","volume":"30","author":"S Ito","year":"2013","unstructured":"Ito, S. & Barrett, A. J. Gauchers disease\u2013a reappraisal of hematopoietic stem cell transplantation. Pediatr. Hematol. Oncol. 30, 61\u201370 (2013).","journal-title":"Pediatr. Hematol. Oncol."},{"key":"17148_CR10","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3109\/08880018.2013.793757","volume":"30","author":"M Machaczka","year":"2013","unstructured":"Machaczka, M. Allogeneic hematopoietic stem cell transplantation for treatment of Gaucher disease. Pediatr. Hematol. Oncol. 30, 459\u2013461 (2013).","journal-title":"Pediatr. Hematol. Oncol."},{"key":"17148_CR11","first-page":"Cd006974","volume":"10","author":"UR Somaraju","year":"2017","unstructured":"Somaraju, U. R. & Tadepalli, K. Hematopoietic stem cell transplantation for Gaucher disease. Cochrane Database Syst. Rev. 10, Cd006974 (2017).","journal-title":"Cochrane Database Syst. Rev."},{"key":"17148_CR12","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1182\/blood.V80.2.331.331","volume":"80","author":"PH Correll","year":"1992","unstructured":"Correll, P. H., Colilla, S., Dave, H. P. & Karlsson, S. High levels of human glucocerebrosidase activity in macrophages of long-term reconstituted mice after retroviral infection of hematopoietic stem cells. Blood 80, 331\u2013336 (1992).","journal-title":"Blood"},{"key":"17148_CR13","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1089\/hum.1998.9.17-2629","volume":"9","author":"CE Dunbar","year":"1998","unstructured":"Dunbar, C. E. et al. Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease: in vivo detection of transduced cells without myeloablation. Hum. Gene Ther. 9, 2629\u20132640 (1998).","journal-title":"Hum. Gene Ther."},{"key":"17148_CR14","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1182\/blood.V83.9.2737.2737","volume":"83","author":"WJ Krall","year":"1994","unstructured":"Krall, W. J., Challita, P. M., Perlmutter, L. S., Skelton, D. C. & Kohn, D. B. Cells expressing human glucocerebrosidase from a retroviral vector repopulate macrophages and central nervous system microglia after murine bone marrow transplantation. Blood 83, 2737\u20132748 (1994).","journal-title":"Blood"},{"key":"17148_CR15","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1182\/blood.V86.3.1218.1218","volume":"86","author":"R Schiffmann","year":"1995","unstructured":"Schiffmann, R. et al. Transfer of the human glucocerebrosidase gene into hematopoietic stem cells of nonablated recipients: successful engraftment and long-term expression of the transgene. Blood 86, 1218\u20131227 (1995).","journal-title":"Blood"},{"key":"17148_CR16","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/jgm.732","volume":"7","author":"EY Kim","year":"2005","unstructured":"Kim, E. Y. et al. Long-term expression of the human glucocerebrosidase gene in vivo after transplantation of bone-marrow-derived cells transformed with a lentivirus vector. J. Gene Med. 7, 878\u2013887 (2005).","journal-title":"J. Gene Med."},{"key":"17148_CR17","doi-asserted-by":"publisher","first-page":"13819","DOI":"10.1073\/pnas.0606016103","volume":"103","author":"IB Enquist","year":"2006","unstructured":"Enquist, I. B. et al. Effective cell and gene therapy in a murine model of Gaucher disease. Proc. Natl Acad. Sci. USA 103, 13819\u201313824 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"17148_CR18","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/mt.2015.16","volume":"23","author":"M Dahl","year":"2015","unstructured":"Dahl, M. et al. Lentiviral gene therapy using cellular promoters cures type 1 Gaucher disease in mice. Mol. Ther. 23, 835\u2013844 (2015).","journal-title":"Mol. Ther."},{"key":"17148_CR19","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJMra032207","volume":"350","author":"MP McCormack","year":"2004","unstructured":"McCormack, M. P. & Rabbitts, T. H. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 350, 913\u2013922 (2004).","journal-title":"N. Engl. J. Med."},{"key":"17148_CR20","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nmeth.2331","volume":"10","author":"M Ranzani","year":"2013","unstructured":"Ranzani, M. et al. Lentiviral vector-based insertional mutagenesis identifies genes associated with liver cancer. Nat. Methods 10, 155\u2013161 (2013).","journal-title":"Nat. Methods"},{"key":"17148_CR21","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.tig.2018.05.004","volume":"34","author":"RO Bak","year":"2018","unstructured":"Bak, R. O., Gomez-Ospina, N. & Porteus, M. H. Gene editing on center stage. Trends Genet. 34, 600\u2013611 (2018).","journal-title":"Trends Genet."},{"key":"17148_CR22","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nprot.2017.143","volume":"13","author":"RO Bak","year":"2018","unstructured":"Bak, R. O., Dever, D. P. & Porteus, M. H. CRISPR\/Cas9 genome editing in human hematopoietic stem cells. Nat. Protoc. 13, 358\u2013376 (2018).","journal-title":"Nat. Protoc."},{"key":"17148_CR23","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nature20134","volume":"539","author":"DP Dever","year":"2016","unstructured":"Dever, D. P. et al. CRISPR\/Cas9 beta-globin gene targeting in human haematopoietic stem cells. Nature 539, 384\u2013389 (2016).","journal-title":"Nature"},{"key":"17148_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11962-8","volume":"10","author":"N Gomez-Ospina","year":"2019","unstructured":"Gomez-Ospina, N. et al. Human genome-edited hematopoietic stem cells phenotypically correct Mucopolysaccharidosis type I. Nat. Commun. 10, 4045 (2019).","journal-title":"Nat. Commun."},{"key":"17148_CR25","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/nbt.3290","volume":"33","author":"A Hendel","year":"2015","unstructured":"Hendel, A. et al. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat. Biotechnol. 33, 985\u2013989 (2015).","journal-title":"Nat. Biotechnol."},{"key":"17148_CR26","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/nmeth.1674","volume":"8","author":"A Lombardo","year":"2011","unstructured":"Lombardo, A. et al. Site-specific integration and tailoring of cassette design for sustainable gene transfer. Nat. Methods 8, 861\u2013869 (2011).","journal-title":"Nat. Methods"},{"key":"17148_CR27","doi-asserted-by":"publisher","first-page":"e339","DOI":"10.1371\/journal.pbio.0030339","volume":"3","author":"J Novembre","year":"2005","unstructured":"Novembre, J., Galvani, A. P. & Slatkin, M. The geographic spread of the CCR5 Delta32 HIV-resistance allele. PLoS Biol. 3, e339 (2005).","journal-title":"PLoS Biol."},{"key":"17148_CR28","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/382722a0","volume":"382","author":"M Samson","year":"1996","unstructured":"Samson, M. et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382, 722\u2013725 (1996).","journal-title":"Nature"},{"key":"17148_CR29","doi-asserted-by":"crossref","unstructured":"Bak, R. O. et al. Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR\/Cas9 and AAV6. Elife 6, e27873 (2017).","DOI":"10.7554\/eLife.27873"},{"key":"17148_CR30","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1046\/j.1365-2567.2001.01256.x","volume":"103","author":"PJ Gough","year":"2001","unstructured":"Gough, P. J., Gordon, S. & Greaves, D. R. The use of human CD68 transcriptional regulatory sequences to direct high-level expression of class A scavenger receptor in macrophages in vitro and in vivo. Immunology 103, 351\u2013361 (2001).","journal-title":"Immunology"},{"key":"17148_CR31","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1038\/gt.2011.195","volume":"19","author":"MC Levin","year":"2012","unstructured":"Levin, M. C. et al. Evaluation of macrophage-specific promoters using lentiviral delivery in mice. Gene Ther. 19, 1041\u20131047 (2012).","journal-title":"Gene Ther."},{"key":"17148_CR32","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1189\/jlb.1108689","volume":"85","author":"KJ Way","year":"2009","unstructured":"Way, K. J. et al. The generation and properties of human macrophage populations from hemopoietic stem cells. J. Leukoc. Biol. 85, 766\u2013778 (2009).","journal-title":"J. Leukoc. Biol."},{"key":"17148_CR33","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1182\/blood-2010-02-271841","volume":"116","author":"SP McDermott","year":"2010","unstructured":"McDermott, S. P., Eppert, K., Lechman, E. R., Doedens, M. & Dick, J. E. Comparison of human cord blood engraftment between immunocompromised mouse strains. Blood 116, 193\u2013200 (2010).","journal-title":"Blood"},{"key":"17148_CR34","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1089\/biores.2014.0008","volume":"3","author":"AS Wiekmeijer","year":"2014","unstructured":"Wiekmeijer, A. S. et al. Sustained Engraftment of cryopreserved human bone marrow CD34(+) cells in young adult NSG mice. Biores. Open Access 3, 110\u2013116 (2014).","journal-title":"Biores. Open Access"},{"key":"17148_CR35","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.immuni.2007.05.001","volume":"26","author":"MG Manz","year":"2007","unstructured":"Manz, M. G. Human-hemato-lymphoid-system mice: opportunities and challenges. Immunity 26, 537\u2013541 (2007).","journal-title":"Immunity"},{"key":"17148_CR36","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1182\/blood-2010-08-301507","volume":"117","author":"E Billerbeck","year":"2011","unstructured":"Billerbeck, E. et al. Development of human CD4+FoxP3+ regulatory T cells in human stem cell factor-, granulocyte-macrophage colony-stimulating factor-, and interleukin-3-expressing NOD-SCID IL2Rgamma(null) humanized mice. Blood 117, 3076\u20133086 (2011).","journal-title":"Blood"},{"key":"17148_CR37","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1038\/leu.2010.158","volume":"24","author":"M Wunderlich","year":"2010","unstructured":"Wunderlich, M. et al. AML xenograft efficiency is significantly improved in NOD\/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3. Leukemia 24, 1785\u20131788 (2010).","journal-title":"Leukemia"},{"key":"17148_CR38","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1182\/blood-2010-06-293902","volume":"116","author":"E Lukina","year":"2010","unstructured":"Lukina, E. et al. Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study. Blood 116, 4095\u20134098 (2010).","journal-title":"Blood"},{"key":"17148_CR39","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s10545-012-9528-4","volume":"36","author":"NJ Weinreb","year":"2013","unstructured":"Weinreb, N. J. et al. Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment. J. Inherit. Metab. Dis. 36, 543\u2013553 (2013).","journal-title":"J. Inherit. Metab. Dis."},{"key":"17148_CR40","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/j.1399-0004.2007.00769.x","volume":"71","author":"J Charrow","year":"2007","unstructured":"Charrow, J., Dulisse, B., Grabowski, G. A. & Weinreb, N. J. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease. Clin. Genet. 71, 205\u2013211 (2007).","journal-title":"Clin. Genet."},{"key":"17148_CR41","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1006\/bcmd.1998.0195","volume":"24","author":"IJ Cohen","year":"1998","unstructured":"Cohen, I. J. et al. Low-dose high-frequency enzyme replacement therapy prevents fractures without complete suppression of painful bone crises in patients with severe juvenile onset type I Gaucher disease. Blood Cells Mol. Dis. 24, 296\u2013302 (1998).","journal-title":"Blood Cells Mol. Dis."},{"key":"17148_CR42","doi-asserted-by":"crossref","unstructured":"Ryan, E., Seehra, G., Sharma, P. & Sidransky, E. GBA1-associated parkinsonism: new insights and therapeutic opportunities. Curr. Opin. Neurol. 32, 589\u2013596 (2019).","DOI":"10.1097\/WCO.0000000000000715"},{"key":"17148_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1079-4","volume":"14","author":"M Wilke","year":"2019","unstructured":"Wilke, M. et al. Evaluation of the frequency of non-motor symptoms of Parkinson\u2019s disease in adult patients with Gaucher disease type 1. Orphanet J. Rare Dis. 14, 103 (2019).","journal-title":"Orphanet J. Rare Dis."},{"key":"17148_CR44","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1182\/blood.V90.1.43.43_43_48","volume":"90","author":"E Ponce","year":"1997","unstructured":"Ponce, E., Moskovitz, J. & Grabowski, G. Enzyme therapy in Gaucher disease type 1: effect of neutralizing antibodies to acid beta-glucosidase. Blood 90, 43\u201348 (1997).","journal-title":"Blood"},{"key":"17148_CR45","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/S1079-9796(03)00012-3","volume":"30","author":"H Zhao","year":"2003","unstructured":"Zhao, H., Bailey, L. A. & Grabowski, G. A. Enzyme therapy of gaucher disease: clinical and biochemical changes during production of and tolerization for neutralizing antibodies. Blood Cells Mol. Dis. 30, 90\u201396 (2003).","journal-title":"Blood Cells Mol. Dis."},{"key":"17148_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-7-102","volume":"7","author":"TM Cox","year":"2012","unstructured":"Cox, T. M. et al. Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study. Orphanet J. Rare Dis. 7, 102 (2012).","journal-title":"Orphanet J. Rare Dis."},{"key":"17148_CR47","doi-asserted-by":"publisher","first-page":"121","DOI":"10.4103\/0971-6866.19530","volume":"11","author":"E Beurtler","year":"2005","unstructured":"Beurtler, E. The treatment of Gaucher disease in countries with limited health care resources. Indian J. Hum. Genet. 11, 121\u2013127 (2005).","journal-title":"Indian J. Hum. Genet."},{"key":"17148_CR48","first-page":"1002","volume":"24","author":"L Nalysnyk","year":"2018","unstructured":"Nalysnyk, L., Sugarman, R., Cele, C., Uyei, J. & Ward, A. Budget impact analysis of eliglustat for the treatment of Gaucher disease type 1 in the United States. J. Manag. Care Spec. Pharm. 24, 1002\u20131008 (2018).","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"17148_CR49","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/MPH.0b013e3182050945","volume":"33","author":"A Gassas","year":"2011","unstructured":"Gassas, A. et al. Long-term adaptive functioning outcomes of children with inherited metabolic and genetic diseases treated with hematopoietic stem cell transplantation in a single large pediatric center: parents\u2019 perspective. J. Pediatr. Hematol.\/Oncol. 33, 216\u2013220 (2011).","journal-title":"J. Pediatr. Hematol.\/Oncol."},{"key":"17148_CR50","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/S0140-6736(95)92597-X","volume":"345","author":"PM Hoogerbrugge","year":"1995","unstructured":"Hoogerbrugge, P. M. et al. Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation. Lancet (Lond., Engl.) 345, 1398\u20131402 (1995).","journal-title":"Lancet (Lond., Engl.)"},{"key":"17148_CR51","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1259\/0007-1285-60-720-1189","volume":"60","author":"F Starer","year":"1987","unstructured":"Starer, F., Sargent, J. D. & Hobbs, J. R. Regression of the radiological changes of Gaucher\u2019s disease following bone marrow transplantation. Br. J. Radiol. 60, 1189\u20131195 (1987).","journal-title":"Br. J. Radiol."},{"key":"17148_CR52","first-page":"77","volume":"30","author":"H Yabe","year":"2005","unstructured":"Yabe, H. et al. Secondary G-CSF mobilized blood stem cell transplantation without preconditioning in a patient with Gaucher disease: Report of a new approach which resulted in complete reversal of severe skeletal involvement. Tokai J. Exp. Clin. Med. 30, 77\u201382 (2005).","journal-title":"Tokai J. Exp. Clin. Med."},{"key":"17148_CR53","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/j.1651-2227.1990.tb11535.x","volume":"79","author":"A Erikson","year":"1990","unstructured":"Erikson, A. et al. Clinical and biochemical outcome of marrow transplantation for Gaucher disease of the Norrbottnian type. Acta Paediatr. Scand. 79, 680\u2013685 (1990).","journal-title":"Acta Paediatr. Scand."},{"key":"17148_CR54","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1056\/NEJM198407123110203","volume":"311","author":"JM Rappeport","year":"1984","unstructured":"Rappeport, J. M. & Ginns, E. I. Bone-marrow transplantation in severe Gaucher\u2019s disease. N. Engl. J. Med. 311, 84\u201388 (1984).","journal-title":"N. Engl. J. Med."},{"key":"17148_CR55","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1159\/000112184","volume":"13","author":"L Svennerholm","year":"1991","unstructured":"Svennerholm, L., Erikson, A., Groth, C. G., Ringden, O. & Mansson, J. E. Norrbottnian type of Gaucher disease\u2013clinical, biochemical and molecular biology aspects: successful treatment with bone marrow transplantation. Developmental Neurosci. 13, 345\u2013351 (1991).","journal-title":"Developmental Neurosci."},{"key":"17148_CR56","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1203\/00006450-199205000-00019","volume":"31","author":"P Tsai","year":"1992","unstructured":"Tsai, P. et al. Allogenic bone marrow transplantation in severe Gaucher disease. Pediatr. Res. 31, 503\u2013507 (1992).","journal-title":"Pediatr. Res."},{"key":"17148_CR57","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1182\/blood-2014-12-615492","volume":"126","author":"R Sharma","year":"2015","unstructured":"Sharma, R. et al. In vivo genome editing of the albumin locus as a platform for protein replacement therapy. Blood 126, 1777\u20131784 (2015).","journal-title":"Blood"},{"key":"17148_CR58","doi-asserted-by":"publisher","first-page":"15276","DOI":"10.1073\/pnas.2435085100","volume":"100","author":"AP Galvani","year":"2003","unstructured":"Galvani, A. P. & Slatkin, M. Evaluating plague and smallpox as historical selective pressures for the CCR5-Delta 32 HIV-resistance allele. Proc. Natl Acad. Sci. USA 100, 15276\u201315279 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"17148_CR59","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1099\/vir.0.000165","volume":"96","author":"A Falcon","year":"2015","unstructured":"Falcon, A. et al. CCR5 deficiency predisposes to fatal outcome in influenza virus infection. J. Gen. Virol. 96, 2074\u20132078 (2015).","journal-title":"J. Gen. Virol."},{"key":"17148_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3186-6","volume":"18","author":"ME Cahill","year":"2018","unstructured":"Cahill, M. E., Conley, S., DeWan, A. T. & Montgomery, R. R. Identification of genetic variants associated with dengue or West Nile virus disease: a systematic review and meta-analysis. BMC Infect. Dis. 18, 282 (2018).","journal-title":"BMC Infect. Dis."},{"key":"17148_CR61","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2009-12-256461","volume":"116","author":"I Visigalli","year":"2010","unstructured":"Visigalli, I. et al. The galactocerebrosidase enzyme contributes to the maintenance of a functional hematopoietic stem cell niche. Blood 116, 1857\u20131866 (2010).","journal-title":"Blood"},{"key":"17148_CR62","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/nature15818","volume":"526","author":"L Naldini","year":"2015","unstructured":"Naldini, L. Gene therapy returns to centre stage. Nature 526, 351\u2013360 (2015).","journal-title":"Nature"},{"key":"17148_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09614-y","volume":"10","author":"M Pavel-Dinu","year":"2019","unstructured":"Pavel-Dinu, M. et al. Gene correction for SCID-X1 in long-term hematopoietic stem cells. Nat. Commun. 10, 1634 (2019).","journal-title":"Nat. Commun."},{"key":"17148_CR64","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1182\/blood-2003-05-1558","volume":"103","author":"F Mazurier","year":"2004","unstructured":"Mazurier, F., Gan, O. I., McKenzie, J. L., Doedens, M. & Dick, J. E. Lentivector-mediated clonal tracking reveals intrinsic heterogeneity in the human hematopoietic stem cell compartment and culture-induced stem cell impairment. Blood 103, 545\u2013552 (2004).","journal-title":"Blood"},{"key":"17148_CR65","first-page":"327","volume":"14","author":"KW Chan","year":"1994","unstructured":"Chan, K. W., Wong, L. T., Applegarth, D. & Davidson, A. G. Bone marrow transplantation in Gaucher\u2019s disease: effect of mixed chimeric state. Bone Marrow Transplant. 14, 327\u2013330 (1994).","journal-title":"Bone Marrow Transplant."},{"key":"17148_CR66","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1097\/00007890-199503000-00011","volume":"59","author":"O Ringden","year":"1995","unstructured":"Ringden, O. et al. Ten years\u2019 experience of bone marrow transplantation for Gaucher disease. Transplantation 59, 864\u2013870 (1995).","journal-title":"Transplantation"},{"key":"17148_CR67","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1634\/stemcells.2008-0844","volume":"27","author":"IB Enquist","year":"2009","unstructured":"Enquist, I. B. et al. Successful low-risk hematopoietic cell therapy in a mouse model of type 1 Gaucher disease. Stem Cells (Dayt., Ohio) 27, 744\u2013752 (2009).","journal-title":"Stem Cells (Dayt., Ohio)"},{"key":"17148_CR68","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/mt.2015.16","volume":"23","author":"M Dahl","year":"2015","unstructured":"Dahl, M. et al. Lentiviral gene therapy using cellular promoters cures type 1 Gaucher disease in mice. Mol. Ther. 23, 835\u2013844 (2015).","journal-title":"Mol. Ther."},{"key":"17148_CR69","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/nprot.2011.301","volume":"6","author":"IF Khan","year":"2011","unstructured":"Khan, I. F., Hirata, R. K. & Russell, D. W. AAV-mediated gene targeting methods for human cells. Nat. Protoc. 6, 482\u2013501 (2011).","journal-title":"Nat. Protoc."},{"key":"17148_CR70","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1093\/nar\/gku936","volume":"42","author":"EK Brinkman","year":"2014","unstructured":"Brinkman, E. K., Chen, T., Amendola, M. & van Steensel, B. Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 42, e168 (2014).","journal-title":"Nucleic Acids Res."}],"updated-by":[{"DOI":"10.1038\/s41467-020-18044-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000}}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-17148-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-17148-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-17148-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T18:34:13Z","timestamp":1670265253000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-17148-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,3]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["17148"],"URL":"https:\/\/doi.org\/10.1038\/s41467-020-17148-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,3]]},"assertion":[{"value":"30 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An amendment to this paper has been published and can be accessed via a link at the top of the paper.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.H.P. declares that he is a consultant and has equity interest in CRISPR Tx and Allogene Tx, and he states that neither company has had input or opinions on the subject matter described in this manuscript. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3327"}}